Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure

References

• StrandVKhannaDThe impact of rheumatoid arthritis and treatment on patients’ livesClin Exp Rheumatol2010283 Suppl 59S32S4020576223
   PubMed Web of Science ®Google Scholar
• McInnesIBO’DellJRState-of-the-art: rheumatoid arthritisAnn Rheum Dis201069111898190620959326
   PubMed Web of Science ®Google Scholar
• RathTRubbertADrug combinations with methotrexate to treat rheumatoid arthritisClin Exp Rheumatol2010285 Suppl 61S52S5721044434
   PubMed Web of Science ®Google Scholar
• RedlichKSchettGSteinerGHayerSWagnerEFSmolenJSRheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockadeArthritis Rheum200348123308331914673982
   PubMed Web of Science ®Google Scholar
• CohenSBEmeryPGreenwaldMWRituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksArthritis Rheum20065492793280616947627
   PubMed Web of Science ®Google Scholar
• KeystoneEBurmesterGRFurieRImprovement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapyArthritis Rheum200859678579318512710
   PubMed Web of Science ®Google Scholar
• KeystoneECSchiffMHKremerJMOnce-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum200450235336314872476
   PubMed Web of Science ®Google Scholar
• LipskyPEvan der HeijdeDMSt ClairEWInfliximab and methotrexate in the treatment of rheumatoid arthritisN Engl J Med2000343221594160211096166
   PubMed Web of Science ®Google Scholar
• SeymourHEWorsleyASmithJMThomasSHAnti-TNF agents for rheumatoid arthritisBr J Clin Pharmacol200151320120811298065
   PubMed Web of Science ®Google Scholar
• WeinblattMEKeystoneECFurstDEAdalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA TrialArthritis Rheum2003481354512528101
   PubMed Web of Science ®Google Scholar
• WeinblattMEKremerJMBankhurstADA trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateN Engl J Med199934042532599920948
   PubMed Web of Science ®Google Scholar
• EdwardsJCSzczepanskiLSzechinskiJEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisN Engl J Med2004350252572258115201414
   PubMed Web of Science ®Google Scholar
• EdwardsJCCambridgeGSustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytesRheumatology (Oxford)200140220521111257159
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRFilipowicz-SosnowskaAThe efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trialArthritis Rheum20065451390140016649186
   PubMed Web of Science ®Google Scholar
• FinckhACiureaABrulhartLB cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agentsArthritis Rheum20075651417142317469098
   PubMed Web of Science ®Google Scholar
• FinckhACiureaABrulhartLWhich subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Ann Rheum Dis201069238739319416802
   PubMed Web of Science ®Google Scholar
• PrevooMLvan’t HofMAKuperHHvan LeeuwenMAvan der PutteLBvan RielPLModified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis Rheum199538144487818570
   PubMed Web of Science ®Google Scholar
• FransenJvan RielPLThe Disease Activity Score and the EULAR response criteriaClin Exp Rheumatol2005235 Suppl 39S93S9916273792
   PubMed Web of Science ®Google Scholar
• FriesJFSpitzPKrainesRGHolmanHRMeasurement of patient outcome in arthritisArthritis Rheum19802321371457362664
   PubMed Web of Science ®Google Scholar
• KeystoneEEmeryPPeterfyCGRituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapiesAnn Rheum Dis200968221622118388156
   PubMed Web of Science ®Google Scholar
• PotterCHyrichKLTraceyAAssociation of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritisAnn Rheum Dis2009681697418375541
   PubMed Web of Science ®Google Scholar
• BenucciMManfrediMPuttiniPSAtzeniFPredictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?Autoimmun Rev201091280180320656069
   PubMed Web of Science ®Google Scholar
• QuartuccioLFabrisMSalvinSRheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritisRheumatology (Oxford)200948121557155919789202
   PubMed Web of Science ®Google Scholar
• TakPPRigbyWFRubbert-RothAInhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trialAnn Rheum Dis2011701394620937671
   PubMed Web of Science ®Google Scholar
• StrangfeldAEveslageMKekowJEffectiveness of treatment with rituximab depends on autoantibody status: results from 2 years of experience in the German biologics register RABBIT [Abstract]Arthritis Rheum200960Suppl 101695
   Google Scholar
• IsaacsJDFerracioliGThe need for personalised medicine for rheumatoid arthritisAnn Rheum Dis20117014721068091
   PubMed Web of Science ®Google Scholar